Status:
TERMINATED
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Lead Sponsor:
Amgen
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Relapsed or Refractory Acute Myeloid Leukemia
Eligibility:
All Genders
18-120 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to evaluate the safety and tolerability of AMG 330, administered in combination with pembrolizumab, in participants with relapsed or refractory acute myeloid leu...
Detailed Description
This study will assess the safety and tolerability of AMG 330 in combination with pembrolizumab and whether pembrolizumab will enhance the anti-AML activity of AMG 330. Both cohort 1 and 2 will includ...
Eligibility Criteria
Inclusion
- Key Inclusion criteria
- AML as defined by the WHO Classification persisting or recurring following one or more treatment courses. Except APL
- Eastern Cooperative Oncology Group (ECOG) ≤1
- Key Exclusion criteria
- Active extramedullary AML in the central nervous system.
- Known hypersensitivity to immunoglobulins.
- Non-manageable graft versus host disease.
Exclusion
Key Trial Info
Start Date :
September 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 23 2020
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04478695
Start Date
September 29 2020
End Date
October 23 2020
Last Update
March 8 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope National Medical Center
Duarte, California, United States, 91010
2
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030